These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


87 related items for PubMed ID: 22325119

  • 1. Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury.
    Poeppl W, Zeitlinger M, Donath O, Wurm G, Müller M, Botha F, Illievich UM, Burgmann H.
    Int J Antimicrob Agents; 2012 Apr; 39(4):343-5. PubMed ID: 22325119
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K, Morikawa N, Uehara S, Monden K, Yamada Y, Honda N, Kumon H.
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers.
    Burian B, Zeitlinger M, Donath O, Reznicek G, Sauermann R.
    Antimicrob Agents Chemother; 2012 Jan; 56(1):532-5. PubMed ID: 22083466
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Microdialysis study of cefotaxime cerebral distribution in patients with acute brain injury.
    Dahyot-Fizelier C, Frasca D, Grégoire N, Adier C, Mimoz O, Debaene B, Couet W, Marchand S.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2738-42. PubMed ID: 23571541
    [Abstract] [Full Text] [Related]

  • 11. Doripenem: position in clinical practice.
    Dedhia HV, McKnight R.
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):507-14. PubMed ID: 19485791
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Target site penetration of fosfomycin in critically ill patients.
    Joukhadar C, Klein N, Dittrich P, Zeitlinger M, Geppert A, Skhirtladze K, Frossard M, Heinz G, Müller M.
    J Antimicrob Chemother; 2003 May; 51(5):1247-52. PubMed ID: 12668580
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
    Matthews SJ, Lancaster JW.
    Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges.
    Nalda-Molina R, Dokoumetzidis A, Charkoftaki G, Dimaraki E, Margetis K, Archontaki H, Markantonis S, Boutos N, Sakas D, Vryonis E, Skoutelis A, Valsami G.
    J Antimicrob Chemother; 2012 Jul; 67(7):1722-9. PubMed ID: 22457313
    [Abstract] [Full Text] [Related]

  • 18. Concentrations of Cefuroxime in Brain Tissue of Neurointensive Care Patients.
    Hosmann A, Ritscher LC, Burgmann H, Oesterreicher Z, Jäger W, Poschner S, Knosp E, Reinprecht A, Gruber A, Zeitlinger M.
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203481
    [Abstract] [Full Text] [Related]

  • 19. Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis.
    Tanoue K, Nishi K, Kadowaki D, Hirata S.
    Ther Apher Dial; 2011 Jun; 15(3):327-33. PubMed ID: 21624085
    [Abstract] [Full Text] [Related]

  • 20. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis.
    Deguchi T, Nakane K, Yasuda M, Shimizu T, Monden K, Arakawa S, Matsumoto T.
    Int J Antimicrob Agents; 2010 Jun; 35(6):573-7. PubMed ID: 20226636
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 5.